Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
Genomic Landscape and Therapeutic Implications of Metaplastic Breast Carcinoma: Insights from a Nationwide Database Including Diagnostic Mimickers.
Suzuki S et al.
Pharmaceuticals (basel, Switzerland), 2026
Insights into RAS-driven melanoma and its therapeutic implications.
Chatziioannou E et al.
Cancer Treatment Reviews, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Evolving Features of RASopathies Among Pregnancies With Abnormal Fetal Fluid Collections.
Gulrajani NB et al.
Prenatal Diagnosis, 2025
Somatic Mutations of Thymic Epithelial Tumors Identified in the Prospective THYMOGENE Trial.
Pardini E et al.
Thoracic Cancer, 2025
Gene discovery in extensive dermal melanocytosis reveals multiple mosaic causes.
Knöpfel N et al.
The British Journal of Dermatology, 2025
Clinical and biochemical characteristics of patients with somatic HRAS-mutant pheochromocytoma and paraganglioma.
Wang K et al.
European Journal of Endocrinology, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Somatic and mosaic HRAS mutations in pediatric malignant ectomesenchymoma.
Salomatina AS et al.
Journal of Human Genetics, 2025
Recurrent FGFR2 and PIK3CA Mutations in Sialoblastoma.
Koo SC et al.
Head and Neck Pathology, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Pediatric Embryonal Rhabdomyosarcoma: An Integrated Study of Clinicopathological Features, Pan-cancer Targeted Next-generation Sequencing, and Chromosomal Microarray Analysis from a Single Institution.
Yang B et al.
Virchows Archiv : an International Journal of Pathology, 2025
RAS pathway targeted therapy in patients with DICER1-associated sarcomas.
Zhang L et al.
Npj Precision Oncology, 2025
Targeted treatment of hypophosphatemia with trametinib in HRAS-related mosaic RASopathy.
Mirza A et al.
Orphanet Journal of Rare Diseases, 2025
Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.
Lin YB et al.
Head & Neck, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Burosumab Treatment in a Girl With Cutaneous Skeletal Hypophosphatemia Syndrome: 2-Year Follow-Up.
Del Pino M et al.
American Journal of Medical Genetics. Part A, 2025
Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma.
Wong K et al.
Nature Communications, 2025
VCP's nuclear journey: Initiated by interacting with KPNB1 to repair DNA damage.
Xing Z et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
A Child with Cutaneous-Skeletal Hypophosphatemia Syndrome Caused by a Mosaic HRAS Mutation: Outcome of Treatment with Anti-FGF23 Antibody.
Wu J et al.
Calcified Tissue International, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
The complexity of tobacco smoke-induced mutagenesis in head and neck cancer.
Torrens L et al.
Nature Genetics, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Renal Juxtaglomerular Cell Tumors Exhibit Distinct Genomic and Epigenomic Features and Lack Recurrent Gene Fusions: Comprehensive Molecular Analysis of a Multi-institutional Series.
Michalova K et al.
The American Journal of Surgical Pathology, 2025
Schimmelpenning-Feuerstein-Mims syndrome: a systematic review of clinical cases to identify genotype-phenotype associations.
Zelenova E et al.
Frontiers in Medicine, 2025
Various genetic alterations observed in both benign and malignant oncocytic (Hürthle cell) neoplasms of the thyroid.
Cocelli CJ et al.
Cytojournal, 2025
Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.
Myszka A et al.
Journal of Clinical Medicine, 2024
Expanding the spectrum of low-grade sinonasal adenocarcinoma with biphasic seromucinous differentiation and activating HRAS/AKT1 mutations.
Hadnagy VS et al.
Histopathology, 2024
Case report & review: Bilateral NIFTP harboring concomitant HRAS and KRAS mutation: Report of an unusual case and literature review.
Brogna MR et al.
Molecular Carcinogenesis, 2024
The Potential Utility of RAS Q61R Immunohistochemistry as a Screening Tool in Pre-operative Fine Needle Aspirates of Medullary Thyroid Carcinoma.
Deyette B et al.
Endocrine Pathology, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M et al.
Cancers, 2024
Cancer in Multilineage Mosaic RASopathies due to Pathogenic Variants in HRAS or KRAS: A Systematic Review and Meta-analysis.
Windrich J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors.
Hu Y et al.
Iscience, 2024
Association of Schimmelpenning Syndrome with Astrocytoma (WHO Grade 3): Case Report.
Tumova A et al.
Medicina (kaunas, Lithuania), 2024
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling.
Hirose T et al.
Npj Breast Cancer, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024